Marta Morawska
YOU?
Author Swipe
View article: Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomes
Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomes Open
View article: Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study
Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study Open
View article: RETRACTED: Kalicińska et al. Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG). Cancers 2024, 16, 4168
RETRACTED: Kalicińska et al. Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG). Cancers 2024, 16, 4168 Open
The Cancers journal retracts the article titled “Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG)” [...]
View article: 201 | GUT MICROBIOME‐DERIVED SHORT‐CHAIN FATTY ACID SODIUM BUTYRATE SHAPE THE IMMUNE RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
201 | GUT MICROBIOME‐DERIVED SHORT‐CHAIN FATTY ACID SODIUM BUTYRATE SHAPE THE IMMUNE RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA Open
View article: Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma Open
PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall surv…
View article: Awareness and Knowledge About Preventive Vaccinations Among Patients with Hematological Malignancies
Awareness and Knowledge About Preventive Vaccinations Among Patients with Hematological Malignancies Open
Background: Patients with hematological malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), are at an increased risk of severe infections due to both disease- and therapy-related immunosuppression. This cr…
View article: Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study
Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study Open
View article: Accelerated chronic lymphocytic leukemia – characteristics and retrospective analysis of the Polish Adult Leukemia Study Group
Accelerated chronic lymphocytic leukemia – characteristics and retrospective analysis of the Polish Adult Leukemia Study Group Open
This study represents one of the largest datasets of A-CLL patients and shows its poorer prognosis compared to typical CLL. Chronic lymphocytic leukemia directed therapy should be considered as a treatment modality of choice for A-CLL. R-C…
View article: Correction for: Accelerated chronic lymphocytic leukemia – characteristics and retrospectiveanalysis of the Polish Adult Leukemia Study Group
Correction for: Accelerated chronic lymphocytic leukemia – characteristics and retrospectiveanalysis of the Polish Adult Leukemia Study Group Open
[This corrects the article DOI: 10.5114/mp.2025.148753.].
View article: RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG)
RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG) Open
Background/Objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: The aims of this study were to assess the following: (1) the incidence of pneumonia in CLL…
View article: Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax‐based regimens: A real‐world analysis of Polish Adult Leukemia Group (PALG)
Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax‐based regimens: A real‐world analysis of Polish Adult Leukemia Group (PALG) Open
Background Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims To assess: (1) the incidence of pneumonia in CLL patients treated with venetoclax‐based regimens in a r…
View article: Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemia
Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemia Open
Evidence indicates that there are significant alterations in gut microbiota diversity and composition in patients with hematological malignancies. The present study investigated the oral and intestinal microbiome in patients with chronic l…
View article: Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL Open
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
View article: Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY Open
View article: The evolving landscape of <scp>COVID</scp>‐19 and <scp>post‐COVID</scp> condition in patients with chronic lymphocytic leukemia: A study by <scp>ERIC</scp>, the <scp>European</scp> research initiative on <scp>CLL</scp>
The evolving landscape of <span>COVID</span>‐19 and <span>post‐COVID</span> condition in patients with chronic lymphocytic leukemia: A study by <span>ERIC</span>, the <span>European</span> research initiative on <span>CLL</span> Open
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high‐count monoclonal B …
View article: S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY. Open
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still …
View article: PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Open
Topic: 5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research Background: Growing evidence suggests the impact of structural changes in the intestinal microbiota on the development of hematologic malignanc…
View article: P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Chemoimmunotherapy based on rituximab remains the cornerstone of treating symptomatic patients with Waldenström macroglobulinaemia. Other targeting agents are …
View article: Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group Open
View article: SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA Open
Introduction: Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material and methods: We performed a survey that covered the period of the first and second waves of the sev…
View article: A Stepwise Screening Protocol for Multiple Myeloma
A Stepwise Screening Protocol for Multiple Myeloma Open
Background: Monoclonal gammopathies and multiple myeloma should be screened in the primary care setting. Methods: The screening strategy consisted of an initial interview supported with the analysis of basic laboratory test results and the…
View article: Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group Open
The early responses to induction regimens and adverse events profile were similar for every type of induction treatment. The infusion-related reactions were rare and limited to the 1st dose of obinutuzumab.
View article: Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study Open
BACKGROUND. Infection by SARS-CoV2 remains a worldwide health burden. Previous studies by the ERIC (European Research Initiative on CLL) showed that patients with chronic lymphocytic leukemia (CLL) have a very-high risk of severe Coronavir…
View article: Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL Open
Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-r…
View article: Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL Open
View article: P677: CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP
P677: CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP Open
Background: The introduction of venetoclax into clinical practice has improved the outcome of patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL). The results of the MURANO trial published in March 2018 showed significa…
View article: Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL Open
Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-r…
View article: Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia Open
Background. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. Methods. We performed a r…
View article: Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group Open
Multiple myeloma (MM) is an incurable disease and patients become refractory to the treatment in the course of the disease. Bendamustine-based regimens containing steroids and other agents are among the therapeutic options offered to MM pa…
View article: COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study Open